Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab + atezolizumab + chemotherapy vs pembrolizumab + chemotherapy in first-line advanced non-squamous NSCLC
2022-502031-20-00Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of tiragolumab, atezolizumab and pembrolizumab in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Roche. Primary endpoints: Investigator-Assessed Confirmed Objective Response Rate (ORR) (Phase 2), Investigator-Assessed Progression-Free Survival (PFS) (Phase 2 and Phase 3) and 1 more. Started Jun 2024; status: completed.
02
Drugs
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2022-502031-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502031-20-00.